A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX for the Symptomatic Treatment of Adults With Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice
Latest Information Update: 01 Aug 2021
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms REPOSE
- Sponsors AbbVie; Allergan
- 06 Jun 2021 Results assessing efficacy and safety parameters of 155- 195U onabotulinumtoxinA in participants with chronic migraine from the real- world REPOSE study, presented at the 63rd Annual Scientific Meeting of the American Headache Society.
- 22 Apr 2021 Results assessing the efficacy and safety of onabotulinumtoxinA in participants with chronic migraine, presented at the 73rd Annual Meeting of the American Academy of Neurology.
- 15 Jan 2021 According to an AbbVie media release, Allergan Aesthetics and Allergan will present data from this trial at the TOXINS 2021 Virtual Conference.